| Literature DB >> 32374880 |
Eduardo Espada1,2, Matthew P Cheng1,3, Haesook T Kim4, Ann E Woolley1,3, Jason I Avigan1, Edouard Forcade5, Maria V D Soares2, João F Lacerda2, Sarah Nikiforow1, Mahasweta Gooptu1, Rizwan Romee1, Edwin P Alyea1, Philippe Armand1, Corey S Cutler1, Vincent T Ho1, John Koreth1, Joseph H Antin1, Robert J Soiffer1, Francisco M Marty1,3, Jerome Ritz1.
Abstract
Clinical disease caused by BK virus reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Because of the lack of effective antiviral agents, BK virus-specific T cells are emerging as a potential therapy for BK virus disease, but the immune response to BK virus after allogeneic HCT has not been well characterized. Our study describes reconstitution of BK virus-specific T-cell immunity in 77 adult patients after HCT. All patients had urinary symptoms, and urine was tested for BK virus replication; 33 patients were positive for BK virus (cases), and 44 were negative (controls). In BK virus cases, the median time to first positive test was 75 days (range, 2-511). BK virus cases had lower CD4 T-cell counts 3 to 9 months after transplant, but CD8 T-cell counts were similar in cases and controls. BK virus-specific T cells were identified by cytokine flow cytometry in cryopreserved samples collected prospectively. BK virus-specific CD4 T cells producing T helper 1 (Th1) cytokines recovered quickly after HCT. BK virus-specific T cells were detected more frequently in patients with BK virus reactivation at most time points, and CD4 T cells producing Th1 cytokines were more frequent than BK virus-specific cytolytic CD8 T cells. Early detection of interferon-γ+ and cytolytic BK virus-specific CD4 T cells was associated with lower rates of hematuria among cases. Overall, our study describes recovery of BK virus-specific T cells after HCT and the distinct roles for BK virus-specific T cells in the development and resolution of clinical symptoms.Entities:
Mesh:
Year: 2020 PMID: 32374880 PMCID: PMC7218418 DOI: 10.1182/bloodadvances.2019001120
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529